Checkpoint Therapeutics I...

AI Score

XX

Unlock

4.04
0.00 (0.00%)
At close: Apr 03, 2025, 3:59 PM
4.02
-0.37%
Pre-market: Apr 04, 2025, 04:10 AM EDT

Company Description

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers.

The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells.

It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.

The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies.

The company was incorporated in 2014 and is based in Waltham, Massachusetts.

Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc. logo
Country United States
IPO Date Dec 19, 2016
Industry Biotechnology
Sector Healthcare
Employees 23
CEO James F. Oliviero III, C.F.A.

Contact Details

Address:
95 Sawyer Road
Waltham, Massachusetts
United States
Website https://www.checkpointtx.com

Stock Details

Ticker Symbol CKPT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001651407
CUSIP Number 162828107
ISIN Number US1628282063
Employer ID 47-2568632
SIC Code 2834

Key Executives

Name Position
James F. Oliviero III, C.F.A. President, Chief Executive Officer & Director
William Garrett Gray CPA Chief Financial Officer, Corporate Secretary & Treasurer

Latest SEC Filings

Date Type Title
Apr 03, 2025 4 Filing
Apr 03, 2025 4 Filing
Mar 28, 2025 10-K Annual Report
Mar 28, 2025 8-K Current Report
Mar 17, 2025 SCHEDULE 13G Filing
Mar 17, 2025 SCHEDULE 13G Filing
Mar 11, 2025 SCHEDULE 13D/A [Amend] Filing
Mar 10, 2025 DEFA14A Filing
Mar 10, 2025 DEFA14A Filing
Mar 10, 2025 8-K Current Report